Click on the subcategory below to find drug monographs for that particular area.
Make prescribing decisions with our comparative charts and treatment algorithms.
Quickly and accurately perform clinical calculations.
Download or print easy-to-read disease leaflets for your patients.
The FDA has approved Baxter's BAXJECT III, a new reconstitution system for Advate (Antihemophilic Factor VIII [recombinant]).
Although not a common procedure, the FDA approved the use of leeches in 2004 for amputation situations.
Baxter announced results from a Phase 3 clinical trial evaluating the safety, efficacy, and pharmacokinetics of BAX 111, a recombinant von Willebrand factor (rVWF) for the treatment of bleeding episodes in patients with von Willebrand disease.
Concomitant use of a nonsteroidal anti-inflammatory drug or aspirin in patients with venous thromboembolism receiving anticoagulant therapy is tied to increased risk of bleeding.
Nurse awareness of this treatment option and the patient selection criteria may be a significant ...
Treatment with ipilimumab can prolong survival to more than 10 years in a subgroup of ...
Adding the anti-angiogenic agent nintedanib to docetaxel for the second-line treatment of adenocarcinoma NSCLC provides ...